New drug combo targets tough cancers in early trial
NCT ID NCT06332755
First seen Nov 25, 2025 · Last updated May 10, 2026 · Updated 17 times
Summary
This early-phase study tests a new experimental drug (LB-LR1109) in people with advanced solid tumors like lung, kidney, or skin cancer that no longer respond to standard treatments. The study has two parts: first, the drug is given alone to find the safest dose; second, it is combined with another cancer drug (atezolizumab) for lung cancer patients. The main goals are to check safety, side effects, and the right dose, while also looking for early signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.